Characteristics | PNS involvement | CNS involvement | No NS involvement | NS involvement | Total | p Value* |
---|---|---|---|---|---|---|
Age, years | 62 (+/−11) | 61 (+/−11) | 57 (+/−12) | 61 (+/−11) | 58 (+/−12) | 0.007 |
Female gender | 56/63 (89%) | 3/14 (21%) | 302/318 (95%) | 65/74 (88%) | 367/392 (94%) | 0.024 |
Age at diagnosis, years | 54 (+/−11) | 53 (+/−8) | 51 (+/−13) | 54 (+/−11) | 51 (+/−12) | 0.075 |
Age at symptom onset, years | 48 (+/−12) | 50 (+/−8) | 46 (+/−14) | 48 (+/−12) | 46 (+/−13) | 0.336 |
Corticosteroids | 50/63 (79%) | 9/14 (64%) | 158/318 (50%) | 57/74 (77%) | 215/392 (55%) | <0.001 |
Hydroxychloroquine | 43/63 (68%) | 5/14 (36%) | 173/318 (54%) | 47/74 (63%) | 220/392 (56%) | 0155 |
IMD/ISD | 18/63 (29%) | 7/14 (50%) | 44/318 (14%) | 24/74 (32%) | 68/392 (17%) | <0.001 |
IVIg | 5/63 (8%) | 0/14 (0%) | 4/318 (1%) | 5/74 (7%) | 9/392 (2%) | 0.004 |
Rituximab | 8/63 (13%) | 1/14 (7%) | 12/317 (4%) | 9/74 (12%) | 21/391 (5%) | 0.004 |
ESSDAI | 9.9 (+/−6.8) | 8.1 (+/−6.2) | 4.3 (+/−4.8) | 9.4 (+/−6.8) | 4.8 (+/−5.5) | <0.001 |
Vasculitis | 17/62 (27%) | 4/14 (29%) | 30/318 (9%) | 21/73 (29%) | 51/391 (13%) | <0.001 |
Cryoglobulinemia | 12/53 (23%) | 2/14 (14%) | 44/272 (16%) | 13/64 (20%) | 57/336 (17%) | 0.460 |
Monoclonal component | 10/49 (20%) | 0/10 (0%) | 34/257 (13%) | 10/58 (17%) | 44/315 (14%) | 0.426 |
Anti-SSA antibodies | 30/63 (48%) | 6/14 (43%) | 194/318 (61%) | 34/74 (46%) | 228/392 (58%) | 0.012 |
Anti-SSB antibodies | 14/63 (22%) | 2/14 (14%) | 113/318 (35%) | 16/74 (22%) | 129/392 (33%) | 0.018 |
*Comparison of patients with and without NS involvement.
Anti-SSA, anti-Sjögren's syndrome A antibodies; Anti-SSB, anti-Sjögren's syndrome B antibodies; CNS, central nervous system; IMD/ISD, immunomodulating/immunosuppressive drugs, that is, mycophenolate mofetil, methotrexate, leflunomide, azathioprine and cyclophosphamide; IVIg, intravenous immunoglobulins; NS, nervous system; PNS, peripheral nervous system.